The results of our current studies imply Gas2/βcatenin/Survivin would be more effective therapeutic targets for enhancing apoptosis in CML-LSCs, but Calpastatin/Xiap1 inhibition would promote apoptosis in circulating CML cells (Figure 5). Here, CAST is linked to chronic myelogenous leukemia, BCR-ABL1 positive.